Results 241 to 250 of about 154,650 (346)

The Bidirectional Association Between MASLD and Male Hypogonadism: An Updated Meta‐Analysis

open access: yesAndrology, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) and male hypogonadism are increasingly prevalent, metabolically interrelated conditions. Testosterone (T) deficiency has been implicated in hepatic lipid dysregulation, insulin resistance, and visceral adiposity, whereas MASLD may impair the hypothalamic–pituitary ...
Giorgia Spaggiari   +9 more
wiley   +1 more source

Economic Evaluation of Prolonged Hypothermic Oxygenated Machine Perfusion Enabling Daytime Liver Transplantation

open access: yesArtificial Organs, EarlyView.
DHOPE‐PRO enabled daytime liver transplantation with comparable one‐year transplantation‐related costs versus short‐duration DHOPE. Higher perfusion costs were offset by lower surgery‐related costs, suggesting DHOPE‐PRO can improve scheduling logistics without increasing overall hospital costs.
Linda C. Woltjes   +47 more
wiley   +1 more source

ALBI‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
ALBI‐6, a novel score combining albumin–bilirubin grade and interleukin‐6, showed improved prognostic discrimination compared with established scores in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab, supporting its potential use for risk stratification in this setting.
Paula Bark   +31 more
wiley   +1 more source

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

open access: yesHepatology, 2003
B. A. Neuschwander-Tetri   +1 more
semanticscholar   +1 more source

Review Article: Fibrosis‐4 Index in Steatotic Liver Disease—Past, Present and Future

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
FIB‐4 remains an inexpensive, scalable first‐line triage tool for excluding advanced fibrosis and identifying patients who need second‐line assessment, but it should not be used as a stand‐alone diagnostic or treatment‐selection test. Sequential testing and longitudinal FIB‐4 trajectories may improve risk stratification and prognosis.
Kriti Soni   +6 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

open access: yesBritish Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy